JPRN-UMIN000047934已完成未知
Safety and Efficacy of a Single 48 mm Everolimus-Eluting Stent in Percutaneous Coronary Intervention for Diffuse Coronary Lesions: A propensity score analysis - Safety and Efficacy of a Single 48 mm Everolimus-Eluting Stent in Percutaneous Coronary Intervention for Diffuse Coronary Lesions: A propensity score analysis
agano Municipal Hospita0 个研究点目标入组 130 人开始时间: 2022年6月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Multiple stents without overlap
研究者
相似试验
进行中（未招募）
1 期
EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study.• Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung• Well to moderately differentiated neuroendocrine carcinoma (NET G1/G2) that switched to G3 (confirmed by histology)• Neuroendocrine tumor G3 (NET G3)EUCTR2012-004550-28-DEAIO-Studien-gGmbH
已完成
不适用
Assessment of efficy and safety of everolimus in Japanese patients with mRCCrenal cell carcinomaJPRN-UMIN000009620Tokyo Afinitor Clinical Trial Group200
招募中
2 期
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosisadenoma sebaceumTCTR20180820002Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital15
招募中
1 期
Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, monocentric, prospective study.advanced/ or not resectable well differnciated pancreatic neuroendocrin tumorMedDRA version: 16.1Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000888-41-ITFondazione IRCCS Istituto Nazionale dei tumori43
已完成
2 期
Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinomarenal cell carcinomaJPRN-UMIN000008769Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)120